AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for B Lymphocytic Leukemia

Registry of the German CLL Study Group NCT02863692n/a1 site๐Ÿ“ Dresden German CLL Study Group Whole Genome Sequencing (ChromoSeqยฎ) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592n/a1 site๐Ÿ“ St Louis Washington University School of Medicine Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406Phase 21 site๐Ÿ“ Beijing Hebei Senlang Biotechnology Inc., Ltd. ยท Tests: S1904 CD19 CAR-T A Study to Evaluate Efficacy, Safety, and PK of XEMBIFYยฎ+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107Phase 362 sites๐Ÿ“ Bullhead City๐Ÿ“ Huntington Park๐Ÿ“ St. Petersburg Grifols Therapeutics LLC ยท Tests: Xembify, Placebo CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085Phase 3231 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Anchorage Children's Oncology Group ยท Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: pCAR-19B cells Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT03516617Phase 23 sites๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville๐Ÿ“ Rochester Mayo Clinic ยท Tests: Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) NCT06136559Phase 3206 sites๐Ÿ“ Mobile๐Ÿ“ Gilbert๐Ÿ“ Phoenix Merck Sharp & Dohme LLC ยท Tests: Nemtabrutinib, Ibrutinib, Acalabrutinib A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG NCT06792994n/a2 sites๐Ÿ“ Cologne๐Ÿ“ Ulm German CLL Study Group ยท Tests: Observational A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 328 sites๐Ÿ“ Toronto๐Ÿ“ Copenhagen๐Ÿ“ Aarhus Nord Merck Sharp & Dohme LLC ยท Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial NCT05183854Phase 21 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine Impact of Targeted Therapy on Cancer-Related Cognitive Impairment NCT07638007n/a1 site๐Ÿ“ Rochester University of Rochester NCORP Research Base Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) NCT06428019Phase 370 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Clovis AbbVie ยท Tests: Venetoclax, Acalabrutinib, Obinutuzumab A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia NCT07400029Phase 29 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Basking Ridge Memorial Sloan Kettering Cancer Center ยท Tests: Obecabtagene Autoleucel Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia NCT06793241EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites๐Ÿ“ Hefei๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Juventas Cell Therapy Ltd. ยท Tests: single dose of CNCT19 Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites๐Ÿ“ Bundang Gu๐Ÿ“ Seongnam-si๐Ÿ“ Gyeonggi-do Novartis Pharmaceuticals ยท Tests: Tisagenlecleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites๐Ÿ“ Tรผbingen๐Ÿ“ Tรผbingen University Hospital Tuebingen ยท Tests: CAR-T cells targeting CD19 and CD22 Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies NCT06462248Phase 21 site๐Ÿ“ Hong Kong Chi Kong Li ยท Tests: CUCART19 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site๐Ÿ“ Shenzhen Shenzhen University General Hospital ยท Tests: CAR-T cell Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885Phase 1, Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: CAR19TIF cells, Fludarabine, Cyclophosphamide A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy NCT04227015EARLY Phase 11 site๐Ÿ“ Hangzhou He Huang ยท Tests: CTA101 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant NCT06059391Phase 23 sites๐Ÿ“ Duarte๐Ÿ“ Atlanta๐Ÿ“ Boston City of Hope Medical Center ยท Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hemaโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy